Thromb Haemost 1972; 28(03): 496-508
DOI: 10.1055/s-0038-1649034
Original Article
Schattauer GmbH

The Influence of Acenocumarole on the Fibrinogen-turnover in Normal Subjects, Venous Thrombosis and Congestive Heart Failure

A. P. C. van der Maas
1   Department of Internal Medicine D and Laboratory for Endocrinological Chemistry, Municipal Hospital Bergweg, Rotterdam, Department of Biochemical Research, Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam (the Netherlands)
,
F. A. G Teulings
1   Department of Internal Medicine D and Laboratory for Endocrinological Chemistry, Municipal Hospital Bergweg, Rotterdam, Department of Biochemical Research, Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam (the Netherlands)
,
W Schopman
1   Department of Internal Medicine D and Laboratory for Endocrinological Chemistry, Municipal Hospital Bergweg, Rotterdam, Department of Biochemical Research, Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam (the Netherlands)
,
G. J. H. den Ottolander
1   Department of Internal Medicine D and Laboratory for Endocrinological Chemistry, Municipal Hospital Bergweg, Rotterdam, Department of Biochemical Research, Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam (the Netherlands)
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2018 (online)

Preview

Summary

Using 131Iodine-tagged fibrinogen the influence of acenocumarole on the biological half-life of fibrinogen was investigated in healthy patients, patients with venous thrombosis and patients with congestive heart failure.

In 16 healthy patients the mean t½ was 3.8 days. In two of them after administration of acenocumarole the t½ was lengthened. This supports the opinion of a continuous deposition of fibrin on the vascular endothelium in the hemostatic balance.

In 13 patients with venous thrombosis the mean t½ was 2.45 days, lengthening to the normal range after acenocumarole therapy. The time interval between the start of acenocumarole therapy and the moment of normalization of the t½ was approximately 4 days. The prothrombin time-index at this moment was 2.3 (thrombotest 5%), which argues in favour of a vigorous anticoagulant therapy.

In our 10 patients with congestive heart failure probably venous thrombosis occurred in 40%. Prophylactic anticoagulant therapy as in surgical patients therefore has to be considered.